Southern Research Institute

The Uab Research Foundation

Icagen, Inc.

The United States Government As Represented by the Department of Veterans Affairs

Pfizer Corporation

Pinotbio, Inc.

Bristol-myers Squibb Compnay

Southern Reserach Institute

Mark J Suto

Bini Mathew

Corinne E Augelli-Szafran

Vandana Gupta

Brian Edward Marron

Joanne Murphy-Ullrich

Omar Moukha-Chafiq

Xiaodong Wang

Alan Bradley Fulp

Anupam Agarwal

Serge Beaudoin

George Salvatore Amato

Robert N Atkinson

Anath Shalev

Gu Jing

Rita Cowell

Lance Thielen

Thomas Eugene Christos

Amie M Traylor

Maria Graciela Barolli

Lilli Ann Wolf-Gouveia

Junqin Chen

Jin Soo Lee

Subramaniam Ananthan

Darrick Seconi

Robert Galemmo

Rebecca Boohaker

Hyunyong Cho

Doo Young Jung

Andreas Peter Termin

Peter D J Grootenhuis

John S Kiely

Alan Daniel Brown

Valentina Molteni

Dean Wilson

Christopher Franklin Bigge

Long Mao

Mark Ian Kemp

Shelly Ann Glase

Zhicai Yang

Ashish Kumar Pathak

Mark Robert Barvian

Sharanjeet Kaur Bagal

Angelo J Castellino

Sarah Elizabeth Skerratt

Christopher William West

Tomoyuki Yasunaga

Paul Christopher Fritch

Gregory Pacofsky

Yingjie Lai

Matthew Scott Johnson

Syed Kaleem Ahmed

Takenori Kimura

Duncan Charles Miller

Wolfgang Klute

Marina Fosso Yatchang

Jasim Khan

Ritesh Kumar Srivastava

Suhail Muzaffar

Brain Edward Marron

Anthony Pechulis

Shunichiro Hachiya

Annette Theresa Sakkab

Larry Craswell Walker

Nian Zhuang

Wei Zhang

Laia Malet Sanz

Mohammad Athar

George S Amato

The present disclosure is concerned with purine diamine compounds for the treatment of conditions associated with BRD4, RIP3K, and/or IL6 signaling dysfunction such as, for example, cancer (e.g., lung cancer, skin cancer, bladder cancer, kidney cancer, liver cancer), arsenicosis, arsenic poisoning, inflammation, skin lesions, dysfunction of systemic organs, and skin blisters. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Development of potential antidotes for arsenicals

The present invention relates to pharmaceutical compositions for treating blood cancer, which includes 4'-thio-5-aza-2′-deoxycytidine (Aza-T-dCyd), and methods of treating blood cancer using a composition for oral administration that includes Aza-T-dCyd. The present invention provides a significant blood cancer therapeutic effect without having toxicity in a blood cancer mouse model or a human even with the Aza-T-dCyd dose conventionally known to have toxicity. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Composition for treating blood cancer using 4'-thio-5-Aza-2′-deoxycytidine and uses thereof

The present disclosure is concerned with dipeptide compounds for the treatment of various cancers such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, bladder cancer, thyroid cancer, testicular cancer, pancreatic cancer, endometrial cancer, melanomas, gliomas, leukemias, lymphomas, chronic myeloproliferative disorders, myelodysplastic syndromes, myeloproliferative neoplasms, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Modulators of programmed death-ligand-1 and/or programmed death-ligand-2

The present disclosure is concerned with thioquinolinone compounds for the treatment of disorders associated with heme oxygenase-1 (HO-1) signaling dysfunction such as, for example, kidney diseases (e.g., chronic kidney disease, acute kidney injury). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Compounds for the treatment of acute and chronic kidney disease

The present disclosure is concerned with 2-aminoaryl-5-aryloxazole compounds that are capable of activating NF-κB signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD), and neuromuscular disorders such as, for example, Duchenne muscular dystrophy (DMD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

2-aminoaryl-5-aryloxazole analogs for the treatment of neurodegenerative diseases

The present disclosure is concerned with biaryl aminomaleimide compounds for the treatment of disorders associated with heme oxygenase-1 (HO-1) signaling dysfunction such as, for example, kidney diseases (e.g., chronic kidney disease, acute kidney injury). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

In one aspect, compounds and compositions that inhibit TXNIP expression and/or that lower hepatic glucose production and methods of identifying, making, and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with elevated TXNIP and/or elevated glucagon levels such as, for example, diabetes and associated disorders. Further provided are methods for treating hyperlipidemia or fatty liver disease, optionally associated with elevated TXNIP and/or elevated glucagon levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors

The present disclosure is concerned with 2,5-amino-thiazole compounds that are capable of activating NF-&#x3ba;B signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD), and neuromuscular disorders such as, for example, Duchenne muscular dystrophy (DMD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases

The present disclosure is concerned with piperazine-2,5-diones that are capable of inhibiting TGF-&#x3b2; and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Piperazine-2,5-diones as TGF-beta inhibitors

The present disclosure is concerned with 2-aminoaryl-5-aryloxazole compounds that are capable of activating NF-&#x3ba;B signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD), and neuromuscular disorders such as, for example, Duchenne muscular dystrophy (DMD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present disclosure provides crystalline polymorphs of 5-aza-4'-thio-2&#x2032;-deoxycytidine. The crystalline polymorphs may be formulated in a pharmaceutical composition, optionally in combination with an additional chemotherapeutic agent. The crystalline polymorphs are useful to treat various diseases including blood cancers, such as myelodysplastic syndrome and leukemia. A process for preparing the crystalline polymorphs of 5-aza-4&#x2032;-thio-2&#x2032;-deoxycytidine is also disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Polymorophs of 5-aza-4'-thio-2&#x2032;-deoxycytidine

In one aspect, compounds and compositions that inhibit TXNIP expression and/or that lower hepatic glucose production and methods of identifying, making, and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with elevated TXNIP and/or elevated glucagon levels such as, for example, diabetes and associated disorders. Further provided are methods for treating hyperlipidemia or fatty liver disease, optionally associated with elevated TXNIP and/or elevated glucagon levels.

The present disclosure is concerned with benzoannulene compounds that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, chikungunya, Venezuelan equine encephalitis, dengue, influenza, and zika, using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Benzoannulene derivatives as antiviral agents

Growing community of inventors

Homewood, AL, United States of America

Mark J Suto